<\/p>\n
In fact, Kenvue\u2019s return on invested capital (ROIC) ranks nearly last among its competition. For the first quarter, which ended April 2, Kenvue estimates it raked in sales of $3.85 billion and net income of around $330 million. Mongon previously served as J&J’s executive vice president and worldwide chair of consumer health. Kenvue originally priced its initial public offering at $22 Wednesday night, toward the high end of its target range.<\/p>\n<\/p>\n
The temporary hold will give J&J time to try to win court approval of its $8.9 billion proposed settlement with plaintiffs in the talc cases. A federal bankruptcy judge in April temporarily halted nearly 40,000 talc lawsuits through mid-June. That decision was part of J&J’s second attempt to settle talc claims in bankruptcy proceedings. Kenvue rounded up several J&J executives to helm the company, according to the filing.<\/p>\n<\/p>\n
JNJ’s Consumer Health segment has seen some margin expansion in recent years (Figure 4), but of course there is still room for improvement, especially in terms of cash profitability (estimated free cash flow margin of 17%). Note that I have adjusted the profit figures used in the calculation for litigation-related expenses and gains from divestitures. I consider the adjustment for the former in particular to be very important, as Johnson & Johnson retains the majority of talc-related claims (detailed analysis here) – Kenvue will only be responsible for claims outside the US or Canada. In this update, I’ll take a look at Kenvue’s results to date and discuss what to expect from the upcoming report. In addition, I’ll outline my longer-term expectations for Kenvue and take a look at the company’s brand portfolio, balance sheet quality, and current profitability, as well as discuss a sign that Kenvue’s management could be saving in the wrong places.<\/p>\n<\/p>\n
Kenvue projects that its top line will grow at a compounded annual growth rate of between 3% and 4% through 2025. That again highlights why the business might make more sense for risk-averse dividend investors than for those seeking attractive growth opportunities. https:\/\/broker-review.org\/powertrend\/<\/a> When I use my reverse discounted cash flow (DCF) model to analyze the future cash flow expectations baked into KVUE, I find that shares, even at the midpoint, require optimistic assumptions about margins and growth, and look fully valued.<\/p>\n<\/p>\n The CONNEQT Pulse marks a significant leap forward in precision medicine, making advanced cardiovascular insights accessible at home. By utilising Cardiex’s cutting-edge SphygmoCor technology, this device offers heart health insights once confined to specialised medical settings. Like with other medtech sectors, the nature of that demand will focus just as much on the patient experience as on patient outcomes. Companies that offer minimally invasive procedures will have a competitive edge among patients, as will those that offer value-based care and outcomes-based reimbursement models. We can also expect to see the continued growth of telemedicine-based solutions that leverage mobile applications and wearable devices for remote patient monitoring, real-time data collection and self-management of heart health. Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.<\/p>\n<\/p>\n The weighted-average interest rate on Kenvue’s long-term debt (94% of total debt) is 5.11%, which I believe is very reasonable in the current environment and considering the rating. The maturity profile of Kenvue’s long-term debt is shown in Figure 7 and compared to the company’s free cash flow after dividends over three years, assuming no growth. But of course, it is reasonable to expect Kenvue to roll over some of limefx<\/a> its debt from a cost of capital perspective, especially if interest rates decline in the future. In my view, Kenvue has ample excess free cash flow that it can use for share repurchases and\/or investments in addition to maintenance capital expenditures. As shown in Figure 6, Kenvue’s R&D spending is declining in relative terms – and this obviously cannot be attributed to disproportionately strong sales growth.<\/p>\n<\/p>\n Proceeds from the offering and any profits from related debt-financing transactions will go to J&J, but Kenvue will retain $1.17 billion in cash and cash equivalents. We\u2019ve always believed in the power of new perspectives and insights to drive innovation. That\u2019s why our iconic brands have helped generations take care of themselves and their loved ones for more than 135 years. Use of this site constitutes your consent to application of such laws and regulations.<\/p>\n<\/p>\n Overall, Kenvue said 2022 sales were “well balanced” across the company’s three business divisions. Until then, Kenvue will qualify as a “controlled company” under the corporate governance rules of the NYSE, the filing said. That will allow Kenvue to avoid certain listing standards, including a requirement that the company’s board be composed of a majority of independent directors. We are committed to continuously improving our sustainability efforts through our brands, packaging and operations, delivering on the expectations of today\u2019s consumers. Our Healthy Lives Mission strives to advance the well-being of both your health and the planet\u2019s health. We\u2019re working to improve the sustainability of our products, packaging and operations to build lasting positive change for people, communities and the one planet we call home.<\/p>\n<\/p>\n GAAP diluted EPS in the first quarter of 2024 increased 4% to $3.46, versus $3.32 in the same quarter last year. GAAP operating income for the first quarter of 2024 grew to $1.66 billion, compared with $1.56 billion in the year-ago quarter. GAAP operating margin increased to 16.1%, compared with 14.6% in the first quarter of 2023.<\/p>\n<\/p>\n And products in the essential health division, including baby products, mouthwash and dental rinses, sanitary protection and wound care, saw $4.6 billion in net sales, representing 31% of all-in revenue. Johnson & Johnson’s consumer health business Kenvue priced its https:\/\/forex-review.net\/<\/a> IPO at $22 per share Wednesday, toward the high end of its stated range, in an upsized deal that would bring in about $3.8 billion. While much of the medtech market is dominated by long-term players, investors would be wise not to discount up-and-comers as well.<\/p><\/p>\n","protected":false},"excerpt":{"rendered":" In fact, Kenvue\u2019s return on invested capital (ROIC) ranks nearly last among its competition. For the first quarter, which ended April 2, Kenvue estimates it raked in sales of $3.85 billion and net income of around $330 million. Mongon previously served as J&J’s executive vice president and worldwide chair of consumer health. Kenvue originally priced […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[167],"tags":[],"class_list":["post-3673","post","type-post","status-publish","format-standard","hentry","category-forex-trading"],"_links":{"self":[{"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/posts\/3673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/comments?post=3673"}],"version-history":[{"count":1,"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/posts\/3673\/revisions"}],"predecessor-version":[{"id":3674,"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/posts\/3673\/revisions\/3674"}],"wp:attachment":[{"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/media?parent=3673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/categories?post=3673"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/linearlab.eu\/wp\/wp-json\/wp\/v2\/tags?post=3673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/p>\n